1. Generics Bulletin

Who’s Hired? Medicines For Europe Names Stada’s Eder As President

As IGBA Reveals New Chair And Firms Announce Fresh Appointments

 
• By Dave Wallace

Medicines for Europe names a new president, the IGBA reveals its latest chair, and Chanelle and Xbrane announce fresh faces in key roles, in our latest round-up of off-patent industry appointments.

Industry associations have named new leaders at the start of 2025 (Shutterstock)

European off-patent industry association Medicines for Europe has named Stada’s head of western Europe and Germany, Stephan Eder, to become the industry body’s new president for a two-year term.

Eder – who previously headed up Stada’s businesses in Russia and the CIS and in Eastern Europe, before which he had a ten-year stint at Sandoz, as well...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

Formycon Hopes Stelara Biosimilar Sales To Pull Through FY2025 As Q1 Revenues Slump

 
• By Urtė Fultinavičiūtė

Formycon said it predicted low earnings in the first quarter of 2025, after enjoying milestone payments last year. Now, the pressure is on the growing biosimilars portfolio to pull the company through this year.

Gedeon Richter Feels Biosimilar Model ‘Is Looking For An Equilibrium’

 
• By Dean Rudge

Gedeon Richter’s CEO weighed in on the pricing landscape for biosimilars as the firm admitted the market for biosimilar denosumab was set to be more crowded than it had initially anticipated.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.